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Abstract
Background: Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1
(PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a
patient’s own immune system to increase anti-tumor activity. While immunocheckpoint blockade has shown
promising results, only 20–40 % of patients experience objective clinical benefit. Differences in individual tumor
biology and the presence multiple immune checkpoints present a challenge for treatment. Because radiotherapy
has immunomodulatory effects on the tumor microenvironment, it has the potential to synergize with
immunotherapy and augment tumor response. NCT02318771 is a phase 1 clinical trial designed to investigate the
immunomodulatory effects of radiation therapy in combination with pembrolizumab.
Case presentation: The patient is a 64-year-old male with metastatic clear cell renal cell carcinoma, Fuhrman grade
4, pathologically staged as T3 N0. Metastatic disease was well controlled for several years with sunitinib. Following
disease progression, he was switched to axitinib. When disease progression continued, the patient was enrolled in
NCT02318771, a phase 1 clinical trial combining radiotherapy and pembrolizumab. The patient experienced
unusually rapid disease progression during treatment, which was confirmed by repeated CT scans to rule out
pseudoprogression. Tissue biopsies and peripheral blood draws were obtained before, during, and after treatment.
Samples were analyzed to provide plausible rationale for rapid treatment failure.
Conclusions: Biomarker analysis demonstrated an absence of TILs, which may be a cause of treatment failure as
pembrolizumab works through T cell-dependent mechanisms. Furthermore, the presence of other non-redundant
immune checkpoints in the periphery and tumor microenvironment presents a treatment challenge. Additionally,
the radiation dose and fractionation schedule may have played a role in treatment failure as these factors play a
role in the effect radiotherapy on the tumor microenvironment as well as the potential for synergy with
immunotherapy.
Trial registration: An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in
Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and
Lung Cancer, NCT02318771.
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Background
Pembrolizumab (MK-3475; Pembro) is a humanized IgG4
monoclonal antibody that is directed against the pro-
grammed cell death protein 1 (PD-1). PD-1 is expressed
by T cells and interacts with its ligands programmed cell
death protein ligand 1 (PD-L1) and programmed cell
death protein ligand 2 (PD-L2), which are expressed in
peripheral tissues and dendritic cells, respectively. PD-L1
expression is variable and involved in the prevention of
autoimmunity; however, many tumors upregulate PD-L1
to mediate immune tolerance [1]. By blocking the PD-1
pathway, Pembro can enhance T cell-mediated killing of
tumor cells [2]. It has been approved for the treatment of
melanoma and non-small cell lung cancer; however, only
20–40 % of patients demonstrate clinical benefit with
monotherapy [3–5]. Radiation therapy (RT) is thought to
have immunostimulatory effects by enhancing cancer anti-
gen presentation [6, 7]. Because both modalities work
through immune-mediated mechanisms, combination
therapy has the potential to augment immune activation
by PD-1 checkpoint inhibitors. Preclinical models have
demonstrated synergy between RT and PD-1 blockade
treatments [8], and several clinical trials combining RT
with immunotherapy are underway [9]. A phase 1 clinical
trial (NCT02318771) was designed to investigate the im-
munomodulatory effects of RT/Pembro combination
treatment.
We report clinicopathologic and detailed flow cytometry
data from a patient with metastatic renal cell carcinoma
(RCC) who progressed through combined immunother-
apy and radiation.
Case presentation
A 64-year-old Caucasian gentleman presented with flank
pain and gross hematuria in February 2010. Initial work-
up demonstrated a left renal mass, and a left radical
nephrectomy confirmed clear cell RCC, Fuhrman grade
4, pathologically staged as T3 N0. Additionally, at diag-
nosis, small pulmonary nodules were found that were
later confirmed to be RCC by Pax-8 staining (Fig. 3d).
He was treated with sunitinib from March 2010 until
July 2013, when disease progression occurred. The
patient was then treated with axitinib, until progression
and the development of additional pulmonary nodules in
November 2014.
The patient was thereafter enrolled in a clinical trial
(NCT02318771). The trial schema is illustrated in Fig. 1.
The trial enrolls patients with metastatic lung cancer,
melanoma, head and neck cancer, or RCC. The primary
objective is to determine immune activation from single
dose 8 Gy vs. fractionated palliative radiotherapy (4 Gy
×5), which is either preceded by one cycle of Pembro or
followed by Pembro that continues until disease progres-
sion or grade 3 or greater toxicities. Our patient was
randomized to group A2, (Fig. 2d) in which he was given
a course of palliative RT dose (20 Gy in five fractions to
his left chest wall lesion), (Fig. 3a and b) followed by
adjuvant Pembro 200 mg once every 3 weeks intraven-
ously. After 5 cycles of treatment, CT scans in May 2015
(Fig. 2b) and a confirmatory scan in June 2015 (Fig. 2c)
revealed progression when compared to his baseline
scans taken in February 2015 (Fig. 2a). Patient tolerated
the combined therapy well without any toxicities and
Fig. 1 Clinical trial schema. Patients with metastatic or recurrent head and neck cancer, renal cell carcinoma, or non-small cell lung cancer were
randomized to either receive pembrolizumab pre-treatment or no pembrolizumab pre-treatment. Patients were again randomized to receive a
single dose of 8 Gy of radiation or five doses of 4 Gy of radiation. Tumor biopsies were obtained at the beginning of the trial as well as 3–10 days
following the last dose of RT. Following RT, all patients received 200 mg of pembrolizumab every 3 weeks
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had no complaints of chest wall or sternal discomfort or
respiratory symptoms although imaging studies demon-
strated an increased size of the left chest wall lesion,
multiple bilateral pulmonary nodules, and an anterior
mediastinal mass accompanied with erosion of the
sternum and the third, fourth, and fifth ribs, as well as
new nodules that were not previously identified. As per
protocol, the patient was removed from trial following
disease progression. A biopsy of the chest wall lesion
was performed to rule out possible pseudoprogression.
Peripheral blood draws and tumor biopsies of his
target lesion were obtained before, after RT in early
March, and at the time of progression in late June. Flow
cytometry analysis of his circulating CD3+ T lympho-
cytes revealed a minor change in the proportion of CD8
+ lymphocytes from baseline (28 %) compared to post-
radiation (24 %) and post-Pembro treatment (24 %).
However, due to a decrease in the numbers of circulat-
ing CD3+ T cells from 1.2 × 106/ml before study to 0.9 ×
106/ml at the conclusion of the trial, there was an overall
reduction in the number of circulating CD8 T cells by
40 %. This was accompanied by a somewhat lesser 22 %
decrease in the numbers of circulating CD4+ T cells
post-Pembro. Over the course of treatment, PD1 expres-
sion was strongly increased on subsets of circulating
CD8+ and CD8− CD3+ T cells (Fig. 4a, b). Changes in
the expression of other immune checkpoint markers
including Tim-3 and Lag-3 were also assessed by flow
cytometry. Both were detected on circulating CD8+
cells, but there were no significant differences in expres-
sion between cells obtained before and after treatment
noted (Fig. 4a, b).
There was an absence of tumor-infiltrating lympho-
cytes (TILs) on tumor biopsy by histological analysis.
This finding was confirmed by RT-PCR analyses of
tumor biopsies, which failed to detect CD4 or CD8 tran-
scripts (Fig. 4d). RT-PCR also failed to detect TNF-alpha
or CD11b transcripts before and after radiotherapy. PD-
L1 transcripts were strongly upregulated in biopsy tissue
following RT, which was confirmed by immunohisto-
chemistry (Fig. 4c).
Discussion
The investigational agent Pembro works through antag-
onism of PD-1 pathway on activated T cells. While PD-1
blockade monotherapy has led to impressive results
Fig. 2 CT scans of the patient demonstrate disease progression. a Axial and coronal CT images taken before treatment. The white arrow indicates
the target lesion, which was biopsied before and after RT. This lesion in the left anterior chest wall measured 20 × 13 mm. Other nodules
included the right lower lobe lesion measuring 8 × 8 mm and the right lung base measuring 5 × 2 mm. b Axial and coronal CT images of patient
3 months post-treatment demonstrating disease progression. The left anterior chest wall mass increased from 20 × 13 mm to 24 × 21 mm. The
right lower lobe nodule increased in size from 8 × 8 mm to 18 × 16 mm, and the right lung base increased from 5 × 2 mm to 11 × 13 mm. c Axial
and coronal CT images 4 months post-treatment were performed to rule out pseudoprogression. True radiographic progression was confirmed.
The left anterior chest wall mass increased from 24 × 21 mm to 30 × 29 mm. The right lower lobe nodule remained 18 × 16 mm, and the right
lung base increased from 11 × 13 mm to 17 × 12 mm. d Schema displaying the patient’s course of treatment. The patient was randomized to
group A2. He received no pembrolizumab pre-treatment, 20 Gy of radiation delivered over the course of five treatments followed by 200 mg of
pembrolizumab every 3 weeks until disease progression
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against some treatment resistant tumors [10], single
checkpoint blockade only produces an objective clinical
response in approximately 20–40 % of patients [3–5]. It
appears that PD-L1 expression may be predictive of
treatment response, but not all patients with PD-L1-
positive tumors respond [11]. Because there are multiple,
non-redundant mediators of immune tolerance in the
microenvironment, tumors may escape immune surveil-
lance through other pathways that are not disrupted by
Pembro [1].
Activated T cells may express multiple immunomodu-
latory cell surface receptors, such as TIM-3, LAG-3, and
CTLA-4 [12]. When these receptors are engaged by
their respective ligands, T cell activity is repressed. Flow
cytometry of peripheral blood mononuclear cells re-
vealed TIM-3 and Lag-3 expression on circulating T
lymphocytes, which suggests multiple pathways may
have been utilized by the metastatic growths to evade
the immune response. Preclinical animal models have
demonstrated increased efficacy when various combina-
tions of different immune checkpoint blockade and RT
are utilized when compared to monotherapy [8, 13–16].
Of note is the lack of TILs, which was confirmed by
RT-PCR and histological study and the 40 % decrease in
total circulating CD8-positive T cells. Because Pembro
acts through a T cell-dependent mechanism, a decrease
in circulating CD8s and a lack of TILs is a possible cause
for treatment failure [17]. The presence of TILs has been
shown to be predictive treatment response in both melan-
oma and mismatch repair-deficient colon cancer [18, 19],
but more work must be done to demonstrate predictive
value in other solid tumors [20]. The lack of TILs in this
patient may be attributed to a dysregulation of chemokine
secretion, resulting in a failure to attract migrating
lymphocytes into target tissue. This hypothesis is
supported by the failure of RT-PCR to detect TNF-alpha
transcripts in tumor biopsies before and after treatment as
TNF-alpha has a role in lymphocytic migration. The
Fig. 3 a Coronal image of the radiation treatment planning CT depicting the treatment portal, organs at risk, and isodose lines. The white arrow
points to the 20-Gy isodose line. b Axial image of the radiation treatment planning CT depicting the dose wash and dose falloff into the left lung.
Red depicts the prescription isodose line of 20 Gy, which was given over five daily fractions. The white arrow points to the 20-Gy isodose line. c
The immunomodulatory effects of ionizing radiation has the potential for synergism with pembrolizumab. d A tumor biopsy of chest wall lesion
was stained with Pax-8 to confirm metastatic RCC
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lengthy treatment with tyrosine kinase inhibitors, axitinib,
and sunitinib, may have also inhibited lymphocytic infil-
tration. Both drugs have been shown to have immuno-
modulatory effects that can disrupt the function of both T
cells and dendritic cells [21–24].
In addition to inducing apoptosis through free radical
damage, RT has the potential to enhance T cell recogni-
tion of malignant tissue through the induction of MHC-
I expression and generation of neoantigens [25]. These
alterations in the immune microenvironment can result
in regression of the target lesion, as well as distant
metastases. Reduction in the size of non-irradiated
lesions following RT is a rare phenomenon called the
abscopal effect, which is hypothesized to be mediated
through the increased immune activation that can result
following RT [26]. The abscopal effect has been reported
in several cases of RCC [27]. It can result in dramatic
clinical improvement, and there has been some success
in recreating it in clinical trials [28]. Because this patient
was unable to generate a sufficient immune response,
anti-tumor activity was observed in neither distant nor
target lesions.
Fig. 4 Flow cytometry analysis of peripheral blood T cells before (a) and after treatment (b). The expression of the immune markers (from left to
right) TIM-3, Lag-3, and PD-1, on CD3+ T cells counter-stained for CD8 were analyzed. c Immunostaining of tumor cells following radiotherapy for
PD-L1. d Real-time quantitative RT-PCR analysis of baseline and post radiotherapy tumor biopsy specimens for the content of mRNAs specific for
the T cell markers CD4, CD8, the checkpoint inhibitor PD-L1, the pro-inflammatory cytokine TNFα, and the macrophage marker CD11b. ND none
detected. The quantitative RT-PCR assay uses artificial gene standards for positive controls and is sensitive to the level of 10 copies per sample
Alexander et al. Journal of Hematology & Oncology  (2016) 9:96 Page 5 of 7
The primary end point of our trial is to explore the
immune modulating effects of RT such as upregulation
of PDL1 in several cancer types. While this clinical trial
is still ongoing, PD-L1 transcripts in this patient’s tumor
biopsy tissue were greatly increased following RT. Other
studies have found PD-L1 to be upregulated following
RT and that increased anti-tumor activity was observed
by combining RT with PD-L1 blockade [29]. Import-
antly, this benefit was only observed when concurrent
treatment was delivered and not when RT was delivered
prior to PD-L1 blockade [30]. Our patient was random-
ized to receive Pembro following RT, which may have
made treatment failure more likely.
To further complicate issues, the dosage and method
of delivery of RT is an important factor in treatment
outcome as preclinical models have shown that RT can
either stimulate or repress the immune system based on
delivery and dosage [31]. A preclinical study demon-
strated that the abscopal effect and synergism with an
anti-CTLA-4 monoclonal antibody was seen only when
RT was hypofractionated and not with other RT frac-
tionations [32]. There is also risk of immunosuppression
as RT can increase the proportion of immunosuppressive
T regulatory cells (Treg) [33]. Additionally, RT may ex-
acerbate pre-existing M2 macrophage polarization in the
tumor microenvironment, decrease the CD8 to Treg ra-
tio, and induce apoptosis of TILs [34]. The optimal dose
and delivery needed to optimize therapy may also be
dependent on the biology of each individual tumor and
therefore requires further study.
There are many ongoing attempts to use various combi-
nations of immune checkpoint blockades and RT to
maximize anti-tumor activity [35, 36]. Results so far have
been encouraging. Patient subset analysis has found that
RT/ipilimumab treatment-resistant melanoma patients
with high PD-L1 expression benefit from PD-L1 blockade
[13]. Additionally, a clinical trial combining nivolumab
and ipilimumab demonstrated an improved clinical
response in melanoma patients when compared to mono-
therapy, with some evidence suggesting PD-L1 positivity
is predictive of longer progression free survival [37, 38].
However, the safety profile of combination therapy is
unknown and optimization requires careful consideration.
Conclusions
In conclusion, we hypothesize that the failure of T lym-
phocytes to migrate into malignant tissue may have
played a role in treatment failure as both RT and Pem-
bro act through T cell-dependent mechanisms. Further
optimization of combined RT and immunotherapy
requires a more in-depth understanding of the tumor
microenvironment. In order to maximize anti-tumor
activity, the presence of multiple, non-redundant check-
point regulators, as well as the dose- and schedule-
dependent immunomodulatory effects of RT, must be
taken into consideration.
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